Delving into the Latest Updates on Inactivated SARS-CoV-2 vaccine (Vero cell) (Beijing Bio-Institute) with Synapse

The SARS-CoV-2 Omicron variant and its sublineages continue to circulate widely. Clinical outcomes with this variant differ among individuals, primarily influenced by host immunity. Previous studies have explored the relationship between immune responses and severe diseases in infected or convalescent patients. However, the impact of vaccine-induced immune responses on disease severity, especially in cases of mild infection following breakthrough infection, remains unclear. This is primarily due to the lack of assessment of immune status in vaccinated individuals before infection. In this study, we aimed to elucidate the causality between virus-specific cellular and humoral immune responses and the severity of symptoms in breakthrough infected patients from a long-term follow-up post-vaccination cohort. A questionnaire survey was conducted to collect general symptoms upon breakthrough infection with the Omicron variants. Plasma levels of specific antibodies (neutralizing antibodies, anti-S IgG, and anti-N IgG) and T cell responses induced by inactivated SARS-CoV-2 vaccine were evaluated. The findings revealed that individuals with milder symptoms, particularly lower peak fever temperatures, exhibited higher antibody levels and enhanced T cell activation and responses prior to infection. This suggests that cellular and humoral immunity induced by inactivated vaccines may provide protection against severe clinical symptoms following breakthrough infection.

01 Feb 2025·Journal of Virological Methods

Quantitative and qualitative analysis of seroconversion after one year of vaccination with inactivated SARS-CoV-2 vaccine (CoronaVac®) in healthcare workers: Cross-sectional analytical study

Article

Author: Fonseca, Fernando Luiz Affonso ; da Silva, Júlia Gomes ; Natário, Inneke Marie van der Heijden ; Veiga, Glaucia Raquel Luciano da ; Sousa, Luiz Vinícius de Alcantara ; Alves, Beatriz da Costa Aguiar ; van der Heijden Natário, Inneke Marie ; Arruk, Viviana Galimberti

A descriptive study was carried out with health professionals in Sao Paulo city. Were included individuals vaccinated with 2 doses of the inactivated vaccine. Demographic, clinical and vaccination information was obtained from professionals with or without comorbidities. Two serological assays were used to identify the presence and quantity of anti-Spike IgG in serum samples. 433 healthy healthcare professionals were included and 58.9 % completed the 4 clinical stages of serological assessment. Among adults and elderly people, 25.2 % had chronic diseases (hypertension 50.5 %, diabetes 10 % and obesity 6.5 %). Most individuals have 95 % protection in the first 3 months after the second dose, and 67.68 % protection after 6 months. Total antibodies ranged from 3 to 10 on the reactivity index, and the anti-RBD IgG levels were high. CoronaVac has a 94 % seroconversion rate after 2 doses and can prevent serious cases and outbreaks of the disease, if used on a large scale.

31 Dec 2024·Human Vaccines & Immunotherapeutics

Comparison of T cells mediated immunity and side effects of mRNA vaccine and conventional COVID-19 vaccines administrated in Jordan

Article

Author: Abu-Qatouseh, Luay ; Jaber, Hatim M. ; Ebdah, Saja ; Jaber, Yazan H. ; Al Haj Mahmoud, Sameer A.

Various COVID-19 vaccines can affect the immune system. Discrepancies have been noted in immune system characteristics, such as T-lymphocyte levels, between vaccinated and non-vaccinated individuals. This study investigates the variations in immune responses among the four administered COVID-19 vaccines, influencing factors, and clinical outcomes in Jordan. A total of 350 adults, who were at least two doses vaccinated, were interviewed and blood samples were collected for subsequent laboratory analyses. The study involved the quantification of T-cells specifically targeting anti-SARS CoV-2 using Flow cytometry analysis. BNT162b2 (Pfizer) recipients displayed significantly higher CD3⁺/CD4⁺ T-helper cell responses (90.84%, 87.46% - 94.22%) compared to non-Pfizer-BioNTech recipients {BBIBP-CorV (Sinopharm) and Sputnik V (Gamaleya Research Institute), then ChAdOx1 nCoV-19 (AstraZeneca)} (83.62%, 77.91% - 89.33%). The CD3⁺/CD8⁺ (T cytotoxic) level was notably elevated in non-Pfizer-BioNTech recipients {Sinopharm and Sputnik V then ChAdOx1 nCoV-19 AstraZeneca (73.94%, 69.38% - 78.49%) compared to BNT162b2 (Pfizer) recipients (58.26%, 53.07% - 63.44%). The CD3⁺ (T-cells) level showed no significant difference between BNT162b2 recipients (73.74%) and non-Pfizer-BioNTech recipients (77.83%), with both types generating T-cells. Comparing two doses of non-Pfizer-BioNTech vaccines with the third dose of BNT162b2 recipients (Pfizer), no difference in the type of immune reaction was observed, with non-Pfizer-BioNTech recipients still stimulating endogenous pathways like cell-mediated cytotoxic effects for cells. All COVID-19 vaccines administered in Jordan were effective, with respect to the total number of T cells. Non-Pfizer-BioNTech had higher in toxic T-cells and Pfizer-BioNTech was higher in helper T-cells that stimulate plasma cells to produce antibodies.

100 Deals associated with Inactivated SARS-CoV-2 vaccine (Vero cell) (Beijing Bio-Institute)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
COVID-19	United Arab Emirates	Beijing Bio-Institute Biological Products Co. Ltd.	09 Dec 2020

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Severe Acute Respiratory Syndrome	Preclinical	Argentina	Laboratorio Elea Phoenix SA	16 Sep 2020
COVID-19	Preclinical	Egypt	China National Biotec Group Co., Ltd.	16 Jul 2020
COVID-19	Preclinical	Jordan	China National Biotec Group Co., Ltd.	16 Jul 2020
COVID-19	Preclinical	Bahrain	China National Biotec Group Co., Ltd.	16 Jul 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05249816 (Pubmed \| Nat Commun) Manual	Phase 3	COVID-19	3,147,869	BBIBP-CorV	uqugrybrni(fnvjvtaehl) = lfeeqbmlye ttjhqghmjt (gtkrkdgqhe, 82.2 - 89.0) View more	-	09 Jun 2022
ChiCTR2000034780 \| NCT04510207 (CNBG2020003SQ, Pubmed) Manual	Phase 3	COVID-19	40,382	Inactivated COVID-19 Vaccine WIV04	(jimynjxvos) = arftkmemru xcvgbxqrbs (asmbsgqtpm ) View more	Positive	26 May 2021
	Phase 3	COVID-19	40,382	Inactivated COVID-19 Vaccine HB02	(jimynjxvos) = dfwwigjsku xcvgbxqrbs (asmbsgqtpm ) View more	Positive	26 May 2021